BiotechTubeBiotechTube
Home/Pipeline/LockBody Platform Assets

LockBody Platform Assets

Oncology

Pre-clinicalActive

Key Facts

Indication
Oncology
Phase
Pre-clinical
Status
Active
Company
Centessa Pharmaceuticals

About Centessa Pharmaceuticals

Centessa Pharmaceuticals is a clinical-stage biotech company with a mission to discover and develop transformational medicines for patients. Its core strategy revolves around a portfolio of orexin receptor 2 agonist programs, led by ORX750, targeting significant unmet needs in sleep-wake disorders and broader neuroscience indications. The company is led by a seasoned team of industry veterans and operates with a lean, asset-focused development model to drive programs from discovery to late-stage development efficiently.

View full company profile

Therapeutic Areas

NeuroscienceSleep-Wake DisordersNeurodegenerative DisordersNeuropsychiatric DisordersOncology

Other Oncology Drugs

DrugCompanyPhase
Mvasi (bevacizumab biosimilar)ViatrisApproved
DRL-17822Dr. Reddy's LaboratoriesPhase 2
Biosimilar PortfolioZydus LifesciencesVarious
therascreen Solid TumorQiagenCommercial
GBR 830Glenmark PharmaceuticalsPhase 1
Bevacizumab BiosimilarGlenmark PharmaceuticalsApproved
Biosimilar (Bevacizumab)Ipca LaboratoriesDevelopment
EverolimusAmneal PharmaceuticalsApproved
Lenalidomide (Revlimid generic)Amneal PharmaceuticalsApproved
Alymsys (bevacizumab-maly)Amneal PharmaceuticalsApproved
Pemrydi RTUAmneal PharmaceuticalsApproved
FocinezAmneal PharmaceuticalsApproved